Allogeneic hematopoietic stem cell transplantation in the elderly

Critical Reviews in Oncology/Hematology

Volumn 64, Issue 1, 2007, Pages 49-63

  Shapira, Michael Y ^a   Tsirigotis, P ^a   Resnick, I B ^a   Or, R ^a   Abdul Hai, A ^a   Slavin, S ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Allogeneic stem cell transplantation; Comorbidity; Elderly; High risk patients; Leukemia; Non myeloablative stem cell transplantation (NST); Reduced intensity conditioning (RIC); Septuagenarians

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; FLUDARABINE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; AGING; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; CHRONIC GRAFT VERSUS HOST DISEASE; COMORBIDITY; DEVELOPED COUNTRY; DRUG MEGADOSE; GERIATRIC PATIENT; GRAFT RECIPIENT; GROUPS BY AGE; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; MYELOABLATIVE CONDITIONING; ORGAN TRANSPLANTATION; PLASMA CONCENTRATION-TIME CURVE; PROGNOSIS; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; REVIEW; SURGICAL MORTALITY; THEORETICAL STUDY; WHOLE BODY RADIATION;

AGED; AGED, 80 AND OVER; COMORBIDITY; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; PROGNOSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 34548395746     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2007.01.004     Document Type: Review

References (126)

1. De Lima M., and Champlin R. Unrelated donor hematopoietic transplantation. Rev Clin Exp Hematol 5 (2001) 100-134
2. Wong R., Giralt S.A., Martin T., et al. Reduced intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 102 (2003) 3052-3059
3. Heemskerk M.B.A., Van Walraven S.M., Cornelissen J.J., et al. How to improve the search for an unrelated hematopoietic stem cell donor. Faster is better than more. Bone Marrow Transpl 35 (2005) 645-652
4. Davies S.M., Kollman C., Anasetti C., et al. Engraftment and survival after unrelated donor bone marrow transplantation: a report from the National Marrow Donor Program. Blood 96 (2000) 4096-4102
5. McGlave P.B., Shu X.O., Wen W., et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 year's experience of the national marrow donor program. Blood 95 (2000) 2219-2225
6. Molina A.J., and Storb R.F. Hematopoietic stem cell transplantation in older adults. In: Rowe J.M., Lazarus H.M., and Carella A.M. (Eds). Handbook of bone marrow transplantation (2000), Martin Dunitz Ltd., London, United Kingdom 111-137
7. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukemia Working Parties. Blood 92 (1998) 2322-2333
8. Leith C.P., Kopecky K.J., and Godwin J. Acute myeloid leukaemia in the elderly assessment of multidrug resistance (MDR) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood 89 (1997) 3323-3329
9. Zhu Y.M., Das-Gupta E.P., and Russel N.H. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukaemia. Blood 94 (1999) 733-740
10. Shipp M., Harrington D.P., and Anderson J.R. The International non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329 (1993) 987-994
11. Frank-Stromborg M. Changing demographics in the United States. Implication for health professionals. Cancer 67 Suppl. 6 (1991) 1772-1778
12. Schratzberger G., and Mayer G. Age and renal transplantation: an interim analysis. Nephrol Dial Transpl 18 (2003) 471-476
13. Keswani R.N., Ahmed A., and Keeffe E.B. Older age and liver transplantation: a review. Liver Transpl 10 (2004) 957-967
14. Macrae J., Friedman A.L., Friedman E.A., and Eggers P. Live and deceased donor kidney transplantation in patients aged 75 years and older in the United States. Int Urol Nephrol 37 (2005) 641-648
15. Golberg S.L., Klumpp T.R., Magdalinski A.J., et al. Value of the pre-transplant evaluation in predicting toxic 100-day mortality among blood stem cell and bone marrow recipients. J Clin Oncol 16 (1998) 3796-3802
16. Weisdorf D., Bishop M., Dharan B., et al. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukaemia: comparative toxicity and outcomes. Biol Blood Marrow Transpl 8 (2002) 213-220
17. Robin M., Guardiola P., Dombret H., et al. Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission: risk factors for long term morbidity and mortality. Bone Marrow Transpl 31 (2003) 877-887
18. Fujimaki K., Maruta A., Yoshida M., et al. Severe cardiac toxicity in haematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction. Bone Marrow Transpl 27 (2001) 307-310
19. Hertenstein B., Stefanic M., Schmeiser T., et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J Clin Oncol 12 (1994) 998-1004
20. Jain B., Floreani A.A., Anderson J.R., et al. Cardiopulmonary function and autologous bone marrow transplantation: results and predictive value for respiratory failure and mortality. The University of Nebraska Medical Center Bone Marrow Transplantation Pulmonary Study Group. Bone Marrow Transpl 17 (1996) 561-568
21. McDonald G.B., Hinds M.S., Fisher L.D., et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118 (1993) 255-267
22. Gruss E., Bernis C., Tomas J.F., et al. Acute renal failure in patients following bone marrow transplantation: prevalence, risk factors and outcome. Am J Nephrol 15 (1995) 473-479
23. Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 35 (2000) 181-200
24. Yancik R., Wesley M.N., Ries L.A.G., et al. Comorbidity and age as predictors for risk for early mortality of male and female colon carcinoma patients. A population-based study. Cancer 82 (1998) 2123-2134
25. Hall W.H., Jani A.B., Ryu J.K., Narayan S., and Vijayakumar S. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis 8 (2005) 22-30
26. Lash T.L., Thwin S.S., Horton N.J., Guadagnoli E., and Silliman R.A. Multiple informants: a new method to assess breast cancer patients' comorbidity. Am J Epidemiol 157 (2003) 249-257
27. Charlson M.E., Pompei P., Ales K.L., et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987) 373-383
28. Shahjahan M., Alamo J., de Lima M., et al. Effect of comorbidities on allogeneic hematopoietic stem cell transplant outcomes in AML/MDS patients in first complete remission. Biol Blood Marrow Transpl 10 Suppl. 2 (2004) 12-13
29. Diaconescu R., Flowers C.R., Storer B., et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 104 (2004) 1550-1558
30. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after non-myeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 104 (2004) 961-968
31. Gomez-Nunez M., Martino R., Caballero M.D., et al. Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trial. Bone Marrow Transpl 33 (2004) 477-482
32. Branson K., Chopra R., Kottaridis P.D., et al. Role of non-myeloablative allogeneic stem cell transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 20 (2002) 4022-4031
33. Bosi A., Laszlo D., Labopin M., et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 19 (2001) 3675-3684
34. Slattery J.T., Clift R.A., Buckner C.D., et al. Marrow transplantation for chronic myeloid leukaemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89 (1997) 3055-3060
35. Kashyap A., Wingard J.R., Cagnoni P., et al. Intravenous (IV) vs oral busulfan (Bu) as part of a BU/CY (cyclophosphamide) preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT): decreased incidence of hepatic veno-occlusive disease (VOD), VOD-related mortality and overall 100 day mortality. Bone Marrow Transpl 25 (2000) S33 [abstract]
36. Deeg H.J., Shulman H.M., Anderson J.E., et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55-66 years of age. Blood 95 (2000) 1188-1194
37. Rubin E.H., Andersen J.W., Berg D.T., et al. Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukaemia group B trial in patients with acute myeloid leukaemia. J Clin Oncol 10 (2001) 948-953
38. Mayer R.J., and Sea D.R. Intensive post-remission chemotherapy in adults with acute myeloid leukaemia. N Engl J Med 331 (1994) 896-903
39. Cahn J.Y., Labopin M., Mandelli F., et al. Autologous bone marrow transplantation for first remission acute myeloblastic leukaemia in patients older than 50 years: A retrospective analysis of the European Bone Marrow Transplant Group. Blood 85 (1995) 575-579
40. Gale R.P., Bortin M.M., Van Bekkum D.W., et al. Risk factors for acute graft versus host disease. Br J Haematol 67 (1987) 397-406
41. Nash R.A., Pepe M.S., Storb R., et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 80 (1992) 1838-1845
42. Weisdorf D., Hakke R., Blazar B.R., et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 51 (1991) 1197-1203
43. Doney K., Fisher L., Appelbaum F.R., et al. Treatment of adult acute lymphoblastic leukaemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transpl 7 (1991) 453-459
44. Ringden O., and Nilsson B. Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy. Transplantation 40 (1985) 39-44
45. Bross D.S., Tutschka P.J., Farmer E.R., et al. Predictive factors for acute graft-versus-host disease in patients transplanted with HLA-identical bone marrow. Blood 63 (1984) 1265-1270
46. Hagglund H., Bostrom L., Remberger M., et al. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. Bone Marrow Transpl 16 (1995) 747-753
47. Atkinson K., Horowitz M.M., Gale R.P., et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 75 (1990) 2459-2464
48. Aschan J., and Ringden O. Prognostic factors for long-term survival in leukaemia marrow recipients with special emphasis on age and prophylaxis for graft versus host disease. Clin Transpl 8 (1994) 258-270
49. Storb R., Prentice R.L., Sullivan K.M., et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 98 (1983) 461-466
50. Ochs L.A., Miller W.J., Filipovish A.H., et al. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation. Bone Marrow Transpl 13 (1994) 455-460
51. Carlens S., Ringden O., Remberger M., et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single center center analysis. Bone Marrow Transpl 22 (1998) 755-761
52. Bortin M.M., Gale R.P., Kay H.E., and Rimm A.A. Bone marrow transplantation for acute myelogenous leukaemia. Factors associated with early mortality. JAMA 249 (1983) 1166-1175
53. Thomas E.D., Clift R.A., Fefer A., et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104 (1986) 155-163
54. Beelen D.W., Quabeck K., Mahmoud H.K., et al. Allogeneic bone marrow transplantation for acute leukaemia or chronic myeloid leukaemia in the fifth decade of life. Eur J Cancer Clin Oncol 23 (1987) 1665-1671
55. Goldman J.M., Gale R.P., Horowitz M.M., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 108 (1988) 806-814
56. Barrett A.J., Horowitz M.M., Gale R.P., et al. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood 74 (1989) 862-871
57. Copelan E.A., Biggs J.C., Thompson J.M., et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 78 (1991) 838-843
58. Bacigalupo A., Gualandi F., Van Lint M.T., et al. Multivariate analysis of risk factors for survival and relapse in chronic granulocytic leukemia following allogeneic marrow transplantation: impact of disease related variables (Sokal score). Bone Marrow Transpl 12 (1993) 443-448
59. Sutton L., Kuentz M., Cordonnier C., et al. Allogeneic bone marrow transplantation for adult acute lymphoblastic leukemia in first complete remission: factors predictive of transplant-related mortality and influence of total body irradiation modalities. Bone Marrow Transpl 12 (1993) 583-589
60. Valls A., Algara M., Marrugat J., Carreras E., Sierra J., and Granena A. Risk factors for early mortality in allogeneic bone marrow transplantation. A multivariate analysis on 174 leukaemia patients. Eur J Cancer 29 (1993) 1523-1528
61. Snyder D.S., Chao N.J., Amylon M.D., et al. Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. Blood 82 (1993) 2920-2928
62. Gratwohl A., Hermans J., Niederwieser D., et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transpl 12 (1993) 509-516
63. Rapoport A.P., DiPersio J.F., Martin B.A., et al. Patients > or = age 40 years undergoing autologous or allogeneic BMT have regimen-related mortality rates and event-free survivals comparable to patients < age 40 years. Bone Marrow Transpl 15 (1995) 523-530
64. Davies S.M., Shu X.O., Blazar B.R., et al. Unrelated donor bone marrow transplantation: Influence of HLA A and B incompatibility on outcome. Blood 86 (1995) 1636-1642
65. Sutton L., Chastang C., Ribaud P., et al. Factors influencing outcome in de-novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: A long term study of 71 patients. Blood 88 (1996) 358-365
66. Keating S., Suciu S., de Witte T., et al. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups. Bone Marrow Transpl 17 (1996) 993-1001
67. Frassoni F., Labopin M., Gluckman E., et al. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time-a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT). Bone Marrow Transpl 17 (1996) 13-18
68. Cahn J.Y., Labopin M., Schattenberg A., et al. Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia 11 (1997) 416-419
69. Appelbaum F.R., and Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 12 (1998) 25-29
70. Zikos P., Van Lint M.T., Frassoni F., et al. Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukaemia: a randomised study of low-dose cyclosporin versus low-dose cyclosporin and low-dose methotrexate. Blood 91 (1998) 3503-3508
71. Novitzky N., Thomas V., Hale G., et al. Myeloablative conditioning is well tolerated by older patients receiving T-cell-depleted grafts. Bone Marrow Transpl 36 (2005) 675-682
72. Klingemann H.G., Storb R., Fefer A., et al. Bone marrow transplantation in patients aged 45 years and older. Blood 67 (1986) 770-776
73. Ringden O., Horowitz M.M., Gale R.P., et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 270 (1993) 57-60
74. Du W., Dansey R., Abella E.M., et al. Successful allogeneic bone marrow transplantation in selected patients over 50 years of age-a single institution's experience. Bone Marrow Transpl 21 (1998) 1043-1047
75. De la Camara R., Alonso A., Steegmann J.L., et al. Allogeneic hematopoietic stem cell transplantation in patients 50 years of age and older. Haematologica 87 (2002) 965-972
76. Farag S.S., Elder P.J., Marcucci G., et al. Radiation-free regimens result in similar outcomes of allogeneic hematopoietic progenitor cell transplantation in patients aged > or = 50 years compared to younger adults with low-risk disease. Bone Marrow Transpl 31 (2003) 87-93
77. Hansen J.A., Gooley T.A., Martin P.J., et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukaemia. N Engl J Med 338 (1998) 962-968
78. Yanada M., Emi N., Naoe T., et al. Allogeneic myeloablative transplantation for patients aged 50 years and over. Bone Marrow Transpl 34 (2004) 29-35
79. Clift R.A., Appelbaum F.R., and Thomas E.D. Treatment of chronic myeloid leukaemia by marrow transplantation. Blood 82 (1993) 1954-1956
80. Wallen H., Gooley T.A., Deeg H.J., et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 23 (2005) 3439-3446
81. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
82. Giralt S., Thall P.F., Khouri I., et al. Melphalan and purine-analog containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97 (2001) 631-637
83. Kottaridis P.D., Milligan D.W., Chopra R., et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96 (2000) 2419-2425
84. Sayer H.G., Kroger M., Beyer J., et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transpl 31 (2003) 1089-1095
85. Bacigalupo A. Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic hematopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transpl 33 (2004) 691-696
86. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97 (2001) 3390-3400
87. Alyea E.P., Kim H.T., Ho V., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105 (2005) 1810-1814
88. Valcarcel D., Martino R., Sureda A., et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with haematological malignancies. Eur J Haematol 74 (2005) 144-151
89. + cell selection. Exp Hematol 31 (2003) 1039-1043
90. Perez-Simon J.A., Diez-Campelo M., Martino R., et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol 130 (2005) 394-403
91. Mielcarek M., Martin P.J., Leisenring W., et al. Graftversus-host disease after non-myeloablative versus conventional hematopoietic stem cell transplantation. Blood 102 (2003) 756-762
92. Couriel D.R., Saliba R.M., Giralt S., et al. Acute and chronic graft-versus-host disease after ablative and non-myeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transpl 10 (2004) 178-185
93. Vela-Ojeda J., Garcia-Ruiz Esparza M.A., Tripp-Villanueva F., et al. Allogeneic peripheral blood stem cell transplantation using reduced intensity versus myeloablative conditioning regimens for the treatment of leukemia. Stem Cells Dev 13 (2004) 571-579
94. Massenkeil G., Nagy M., Neuburger S., et al. Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic hematopoietic cell transplantation in acute leukemias. Bone Marrow Transpl 36 (2005) 683-689
95. Dreger P., Brand R., Milligan D., et al. Reduced-intensity conditioning lower treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukaemia: a population-matched analysis. Leukemia 19 (2005) 1029-1033
96. Bertz H., Illerhaus G., Veelken H., et al. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: Comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimen. Ann Oncol 13 (2002) 135-139
97. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 19 12 (2005) 2304-2312
98. Shimoni A., Hardan I., Smem-Tov N., et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose-intensity. Leukemia 20 (2006) 322-328
99. Martino R., Iacobelli S., Brand R., et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108 (2006) 836-846
100. Kojima R., Kami M., Kanda Y., et al. Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 years. Bone Marrow Transpl 36 (2005) 667-674
101. Shapira M.Y., Resnick I.B., Bitan M., et al. Low transplant related mortality with allogeneic stem cell transplantation in elderly patients. Bone Marrow Transpl 34 (2004) 155-159
102. Bertz H., Potthoff K., and Finke J. Allogeneic stem cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 21 (2003) 1480-1484
103. Shimoni A., Kroger N., Zabelina T., et al. Hematopoietic stem cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using a reduced intensity conditioning. Leukemia 19 (2005) 7-12
104. Tsirigotis P., Or R., Bitan M., et al. A non-myeloablative conditioning regimen in allogeneic stem cell transplantation from related and unrelated donors in elderly patients. Haematologica 91 (2006) 852-855
105. De Lima M., Anagnostopoulos A., Munsell M., et al. Nonablative versus reduced-intensity conditioning regimen in the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104 (2004) 865-872
106. Crawley C., Szydlo R., Lalancette M., et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 106 (2005) 2969-2976
107. Or R., Shapira M.Y., Resnick I., et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101 (2003) 441-445
108. Robinson S.P., Goldstone A.H., Mackinnon S., et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100 (2002) 4310-4316
109. Khoury I.F., and Champlin R.E. Nonmyeloablative stem cell transplantation for lymphoma. Semin Oncol 31 (2004) 22-26
110. Jabbour E., Keating M.J., Champlin R.E., and Khoury I.F. Stem cell transplantation for chronic lymphocytic leukemia: Should not more patients get a transplant?. Bone Marrow Transpl 34 (2004) 289-297
111. Van Besien K., Sobocinski K.A., Rowlings P.A., et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92 (1998) 1832-1836
112. Prigozhina T.B., Elkin G., Khitrin S., and Slavin S. Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning. Exp Hematol 32 (2004) 1110-1117
113. Yang I., Weiss L., Abdul-Hai A., Kassir J., Reich S., and Slavin S. Induction of early post-transplant GVL effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of GVHD. Cancer Res 65 (2005) 9735-9740
114. Godfrey W.R., Krampf M.R., Taylor P.A., and Blazar B.R. Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. Blood 103 (2004) 1158-1165
115. Morecki S., Yacovlev E., Gelfand Y., Uzi I., and Slavin S. Cell therapy with pre-immunized effector cells mismatched for minor histocompatible antigens, in the treatment of a murine mammary carcinoma. J. Immunother. 24 2 (2001) 114-121
116. Ji Y.H., Weiss L., Zeira M., et al. Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to up-regulate anti-tumor effects and down-regulate anti-host responses. Bone Marrow Transpl 32 (2003) 495-504
117. Slavin S., Ackerstein A., Morecki S., Gelfand Y., and Cividalli G. Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigens pulsed donor lymphocytes. Bone Marrow Transpl 28 (2001) 795-798
118. Mutis T., Verdijk R., Schrama E., Esendam B., Brand A., and Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 93 (1999) 2336-2341
119. Slavin S., Or R., Aker M., et al. Treatment of resistant leukemia by rIL-2 activated NK cells in recipients of HLA matched and haploidentically mismatched stem cell allografts while avoiding GVHD. 46th American Society of Hematology (ASH) meeting. San Diego, USA, December 4-7, 2004. Blood 104 11 (2004) 379b [abstract 5180]
120. Slavin S., Shapira M., Morecki S., et al. Use of matched or mismatched rIL-2 activated donor lymphocytes positively selected for CD56+ for immunotherapy of resistant leukemia after allogeneic stem cell transplantation, vol. 23. American Society of Clinical Oncology (ASCO), New Orleans, Louisana, USA, June 3-8, 2004 (2004) 560 [abstract 6516]
121. Carlen S., Gilljam M., Chambers B.J., et al. A new method for in vitro expansion of cytotoxic human CD3- CD56+ natural killer cells. Hum Immunol 62 (2001) 1092-1098
122. Naparstek E. The role of the anti-CD20 antibody rituximab in hematopoietic stem cell transplantation for non-Hodgkin's lymphoma. Curr Hematol Rep 4 (2005) 276-283
123. Nath S.V., and Seymour J.F. Cure of a patient with profoundly chemotherapy-refractory primary mediastinal large B-cell lymphoma: role of rituximab, high-dose therapy, and allogeneic stem cell transplantation. Leuk Lymphoma 46 (2005) 1075-1079
124. Morecki S., Lindhofer H., Yacovlev E., Gelfand Y., and Slavin S. Use of tri-functional bispecific antibodies to prevent GVHD induced by allogeneic lymphocytes. Blood 107 4 (2006) 1564-1569
125. Bonini C., Ferrari G., Verzeletti S., et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276 (1997) 1719-1724
126. Prigozhina T.B., Gurevitch O., Zhu J., and Slavin S. Permanent and specific transplantation tolerance induced by a nonmyeloablative treatment to a wide variety of allogeneic tissues: I. Induction of tolerance by a short course of total lymphoid irradiation and selective elimination of the donor-specific host lymphocytes. Transplantation 63 (1997) 1394-1399